Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 18/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.80 |
| ▸ | PIK3CB | P42338 | 15/20 | 0.80 |
| ▸ | PIK3CG | P48736 | 15/20 | 0.80 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.80 |
| ▸ | PLK4 | O00444 | 1/20 | 0.80 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.80 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.80 |
| ▸ | GAK | O14976 | 1/20 | 0.80 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.80 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.80 |
| ▸ | STK16 | O75716 | 1/20 | 0.80 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.80 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.80 |
| ▸ | NQO2 | P16083 | 1/20 | 0.80 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.80 |
| ▸ | JAK1 | P23458 | 1/20 | 0.80 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.80 |
| ▸ | TYK2 | P29597 | 1/20 | 0.80 |
| ▸ | AKT1 | P31749 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29482127 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3C2A | |
| SCHEMBL393696 | 0.90 | PIK3CD (0.81) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2469939 | 0.90 | PIK3CD (0.81) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| Pictilisib SCHEMBL190812 | 0.89 | PIK3CA (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3C2A | |
| Pictilisib SCHEMBL29387739 | 0.89 | PIK3CA (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3C2A | |
| Pictilisib SCHEMBL14859338 | 0.89 | PIK3CA (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3C2A | |
| Pictilisib SCHEMBL29375636 | 0.89 | PIK3CA (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3C2A | |
| SCHEMBL2465953 | 0.89 | PIK3CD (0.79) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2466623 | 0.89 | PIK3CD (0.79) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2436174 | 0.88 | PIK3CA (0.80) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3C2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812444-B1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LTD (GB) | 2015-08-26 | — | — | EP | claimed |
| US-8101607-B2 | Pharmaceutical compounds | F. HOFFMAN-LA ROCHE AG (CH) | 2012-01-24 | — | — | US | claimed |
| US-20100280027-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-04 | — | — | US | claimed |
| US-7776856-B2 | Pharmaceutical compounds | F. HOFFMAN-LA ROCHE AG (CH) | 2010-08-17 | — | — | US | claimed |
| US-20090131429-A1 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2009-05-21 | — | — | US | claimed |
| EP-1812444-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | claimed |
| WO-2006046035-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | claimed |
| CN-110248963-B | anti-CCR 7 antibody drug conjugates | 诺华股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-116096426-A | CCR7 antibody drug conjugates for the treatment of cancer | 诺华股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20220402934-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2022-12-22 | — | — | US | disclosed |
| CN-108341873-B | Antibodies to epidermal growth factor receptor 3(HER3) | 诺华股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-108367003-B | Treatment of breast cancer brain metastasis | 麻省总医院 | 2022-01-21 | — | — | CN | disclosed |
| CN-113195541-A | Antibodies against PMEL17 and conjugates thereof | 诺华股份有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-103080134-A | Antibodies to epidermal growth factor receptor 3(HER3) | NOVARTIS AG | 2013-05-01 | — | — | CN | disclosed |
| US-8101607-B2 | Pharmaceutical compounds | F. HOFFMAN-LA ROCHE AG (CH) | 2012-01-24 | — | — | US | disclosed |
| US-20100280027-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-04 | — | — | US | disclosed |
| US-7776856-B2 | Pharmaceutical compounds | F. HOFFMAN-LA ROCHE AG (CH) | 2010-08-17 | — | — | US | disclosed |
| US-20090131429-A1 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2009-05-21 | — | — | US | disclosed |
| EP-1812444-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006046035-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280027-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3C2B, PIK3C2A | PIK3CD 4/4885PIK3CA 1/4885PIK3CB 5/4885 |
| US-20090131429-A1 | Pharmaceutical compounds | PIK3CA, PIK3C2B, PIK3CD | PIK3CD 3/4885PIK3CA 1/4885PIK3CB 12/4885 |
| US-20220402934-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | PIK3CD 37/4885PIK3CA 57/4885PIK3CB 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.